Menu Philippe sold $28K of SOPH
Menu Philippe (Chief Medical Officer) sold 5,000 shares of SOPHiA GENETICS SA (SOPH) at $5.50 on 2026-06-25 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price, and 10b5-1 status by the CMO, which can influence short-term sentiment but does not constitute new operational or financial guidance.
Market read
Traders may monitor insider activity for sentiment, but this filing alone is unlikely to drive a major repricing without accompanying company-specific news.
What to watch
The article does not disclose total insider ownership changes beyond the post-transaction share count, nor does it provide context on prior sales frequency or any concurrent company catalysts.
Background
The article is an SEC Form 4 insider transaction disclosure for SOPHiA GENETICS SA.
Ticker impact
SOPHiA GENETICS CMO Menu Philippe filed a Form 4 open-market sale of 5,000 shares at $5.5049 on June 25 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely limited and short-lived.
The filing is a routine 10b5-1 planned sale with disclosed price and share count, providing limited incremental information about company prospects.
Market effects
Minimal. Insider sale in a single biotech/genetics company does not materially reset sector expectations.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish information.
Key entities
- issuerSOPHiA GENETICS SA
Subject of the Form 4 insider transaction disclosure.
- insiderMenu Philippe
Chief Medical Officer who executed the open-market sale under a 10b5-1 plan.
